Enzymotec Ltd. (ENZY) Lifted to “Hold” at Zacks Investment Research
Enzymotec Ltd. (NASDAQ:ENZY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. “
Separately, Jefferies Group restated a “hold” rating on shares of Enzymotec in a report on Thursday, August 4th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/enzymotec-ltd-enzy-lifted-to-hold-at-zacks-investment-research.html
Shares of Enzymotec (NASDAQ:ENZY) traded down 4.05% on Tuesday, hitting $7.10. 4,183 shares of the stock were exchanged. The company has a market cap of $161.30 million, a price-to-earnings ratio of 37.37 and a beta of 1.27. Enzymotec has a 52-week low of $6.60 and a 52-week high of $10.32. The company has a 50 day moving average of $7.31 and a 200 day moving average of $8.13.
Enzymotec (NASDAQ:ENZY) last issued its earnings results on Tuesday, August 9th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.04. Enzymotec had a return on equity of 3.12% and a net margin of 8.37%. The firm earned $15 million during the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior year, the business posted $0.11 EPS. The firm’s revenue for the quarter was down 12.7% on a year-over-year basis. Equities research analysts forecast that Enzymotec will post $0.27 earnings per share for the current year.
A number of hedge funds have recently made changes to their positions in ENZY. Acadian Asset Management raised its stake in shares of Enzymotec by 129.8% in the fourth quarter. Acadian Asset Management now owns 118,072 shares of the company’s stock worth $1,157,000 after buying an additional 66,702 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Enzymotec by 42.9% in the first quarter. Acadian Asset Management LLC now owns 168,738 shares of the company’s stock worth $1,523,000 after buying an additional 50,666 shares during the last quarter. Icon Advisers Inc. Co. acquired a new stake in shares of Enzymotec during the first quarter worth approximately $152,000. Algert Global LLC acquired a new stake in shares of Enzymotec during the first quarter worth approximately $190,000. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of Enzymotec by 13.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 19,015 shares of the company’s stock worth $172,000 after buying an additional 2,318 shares during the last quarter. 36.20% of the stock is owned by institutional investors.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.